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Abstract: Objectives: The aim of the present randomized, double-blind, placebo-controlled,
parallel-arm study was to examine the effectiveness of a sub-antimicrobial dose of doxycycline (SDD)
in combination with nonsurgical periodontal therapy, compared to nonsurgical periodontal therapy
alone, on potential gingival crevicular fluid (GCF) biomarkers of periodontal tissue catabolism related
to the clinical outcomes over a 12-month period. Materials and Methods: GCF was collected and
clinical parameters were recorded from 30 periodontitis patients randomized either to an SDD or
placebo group. The SDD group received SDD (20 mg) b.i.d for 3 months plus scaling and root
planing (SRP), while the placebo group was given placebo capsules b.i.d for 3 months plus SRP.
The patients were evaluated every 3 months during the 12-month study period. At each visit,
clinical parameters and GCF sampling were repeated. Matrix metalloproteinase (MMP)-8, MMP-9,
MMP-13, myeloperoxidase (MPO), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase-5
(TRAP-5) were determined by IFMA and ELISA. Results: Significant improvements were observed
in all clinical parameters in both groups over 12 months (p < 0.0125) while the SDD group showed
significantly better reduction in gingival index (GI) and pocket depth and a gain in clinical attachment
compared to the placebo group (p < 0.05). GCF MMP-8 and OPG levels significantly reduced
in the SDD group compared to baseline (p < 0.05). GCF MMP-9 significantly decreased in both
groups compared to baseline (p < 0.05). GCF MPO significantly decreased at 3 and 9 months in
the SDD group, while it significantly decreased at 6 months in the placebo group (p < 0.05). TRAP
and MMP-13 could be detected in none of the samples. Conclusions: The present results indicate
that three months of adjunctive usage of SDD to nonsurgical periodontal therapy compared to
nonsurgical periodontal therapy alone in periodontitis patients results in further improvement of
clinical periodontal parameters and GCF markers of periodontal tissue breakdown over a 12-month
period. Beneficial effects of adjunctive SDD therapy is likely to be related to the reduced levels of two
major periodontitis-associated MMPs, MMP-8 and -9, and their potential oxidative activator MPO.
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1. Introduction
The upregulated host immune-inflammatory response against the microbial challenge is chiefly
mediated by a network of biomarkers that leads to soft- and hard-tissue destruction [1,2]. Matrix
metalloproteinases (MMPs)—critical components of the host response to bacteria—are involved in
inflammatory and destructive cascades in periodontal pathogenesis [3,4]. Interstitial collagenases,
matrix metalloproteinase (MMP)-8, MMP-9, and MMP-13, cleave fibrillar collagens and collagen
fragments, subsequently denaturing the collagen into gelatins [5–8]. Gelatinase MMP-9, found in
the tertiary granules of neutrophils, is capable of cleaving gelatins as well as the non-collagenous
components of the extracellular matrix and basement membrane [5,7]. These MMPs have also been
demonstrated to be secreted by non-leukocytic sources such as epithelial cells, fibroblasts, osteoblasts,
and osteoclasts [1,4,6]. MMP-8, MMP-9, and MMP-13 have been demonstrated to be associated
with the severity of periodontal disease and are promising candidate biomarkers in oral fluids
such as gingival crevicular fluid (GCF), mouthrinse, and saliva [9–15]. Myeloperoxidase (MPO),
a marker of periodontal inflammation, is an oxidative enzyme released from the azurophilic granules
of degranulating neutrophils with potent antimicrobial activity [16–18]. Besides being an indicator of
neutrophil infiltration, the MPO-mediated oxidative pathway can activate proMMPs and contribute to
protease activity [19–21]. The interaction between collagenases, gelatinases, and MPOs is explained
by the oxidative activation of latent collagenases and gelatinases [19,21] and the inactivation of tissue
inhibitors of MMPs by the MPO [22]. It has been shown that MPO/MMP-8 could represent the
discriminatory biomarkers for the site specific diagnosis of periodontitis, and their association might
reflect the disease severity [1,23]. Tartrate-resistant acid phosphatase (TRAP) is a member of the
iron-containing purple acid phosphatases and is specifically expressed in osteoclasts and other cells of
the monocyte–macrophage lineage [24]. During bone resorption, TRAP is secreted from osteoclasts
along with bone matrix products into circulation where its activity reflects the bone resorption rate [25].
Therefore, TRAP is now being investigated as a blood-borne biochemical marker for osteoclastic activity
and bone resorption [25,26]. Serum concentrations of TRAP have been demonstrated to be correlated
with the rate of bone resorption, while osteoprotegrin administration decreased the serum TRAP-b
and reduced osteoclastic bone resorption, which is the hallmark of periodontitis progression [25,27].
Traditional periodontal therapy involves elimination of periodontopathogens by mechanical
debridement such as scaling and root planning (SRP) and surgical procedures in conjunction with
proper plaque control [28]. Beside the possibility of surgical interventions, non-surgical periodontal
therapy may be supported by the use of local or systemic antibiotics. Due to the infective nature of
periodontitis, pharmacological agents such as antiseptics and systemic or locally delivered antibiotics
have been advocated as adjuncts in the nonsurgical treatment of the periodontal infection [29].
However, because of the increasing resistance to antibiotics, greater efforts are being made to find
alternative procedures or new treatment strategies adjunctive to non-surgical periodontal treatment to
avoid surgery and the potential drawbacks of antibiotics [30–33].
Pharmacological modulation of the host response represents an opportunity for the management
of periodontal disease [34]. Doxycycline’s non-antimicrobial properties is based on the inhibition of
the gingival tissues and GCF mammalian collagenase activity of chronic periodontitis [34]. Thereby,
both the connective tissue destruction and alveolar bone resorption were shown to be decreased [34].
Given the host modulatory activity of a sub-antimicrobial dose of doxycycline (SDD), numerous
studies have evaluated the adjunctive effect of SDD therapy in which SDD was prescribed from
2 weeks to 12 months [35–37]. These double-blind, placebo-controlled clinical studies have reported
that a combined regimen of SDD and nonsurgical periodontal therapy provides improvements in
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clinical periodontal parameters in combination with a significant decrease in collagenase activity when
compared to nonsurgical periodontal therapy alone [35–37]. Long-term usage of SDD did not make
the development of TC resistant microorganisms or have any detrimental effect on the periodontal
microflora [38,39].
In the present study the adjunctive effects of SDD on both clinical parameters as well as GCF
levels of biomarkers of periodontal tissue catabolism, including MPO, MMP-8, MMP-9, MMP-13,
and two markers involved in bone turnover, osteoprotegerin (OPG) and TRAP-5, were evaluated in
CP patients over a 12-month period and compared with those obtained by nonsurgical periodontal
therapy alone. The null hypothesis to invalidate was that after a 1-year follow-up, there were no
variations between SRP plus SDD and SRP alone.
2. Material and Methods
2.1. Study Population
Thirty chronic periodontitis patients (31–61 years old) were joined from the Department of
Periodontology, Dentistry School, Ege University, I˙zmir, from 2002–2004. All procedures were
performed according to the principles outlined in the Declaration of Helsinki and its later amendments
or comparable ethical standards on experimentation involving human subjects. Prior to participation
the purpose and procedures were fully explained to the patients. They were entered into the study after
informed consent was obtained. After complete medical and dental histories were taken, periodontitis
was diagnosed according to the clinical and radiographic findings and periodontal history [40]: buccal
or oral clinical attachment loss (CAL) ≥3 mm with pocketing >3 mm is detectable at ≥2 teeth [40].
Study patients had at least 14 teeth and had stage III periodontitis. Presence of a history of any systemic
disease or a known hypersensitivity to any type of tetracycline were exclusion criteria. Subjects if had
received antibiotics or other medicines or periodontal treatment within the past four months were also
excluded. Pregnant or lactating women were not included as well. Subjects were also not heavy users
of alcohol or tobacco. Smoker patients reported to have smoking less than five cigarettes per day.
2.2. Study Design
This randomized, double-blind, placebo-controlled study of 12-month duration was organized
into three phases including screening, treatment, and evaluation. A single examiner (G.E.). evaluated
the eligibility and enrollment of the patients into trials. The periodontal status of each patient
was assessed at the screening phase. Full mouth probing depth (PD) and CAL were recorded.
All measurements were performed with a standard manual probe (Williams probe) at six sites
around each tooth. Full mouth gingival index (GI) [41] and plaque index (PI) [42] scores were also
recorded. The same examiner unaware of the choice of treatment provided were collected all clinical
measurements over the course of the study. Then, subjects were randomized to SDD (n = 15) or placebo
group (n = 15).
GCF samples were collected at baseline examination. Nonsurgical periodontal therapy was carried
out in 4 to 6 sessions by the same clinician. Tooth and root surfaces were instrumented under local
anesthesia until they were free of all deposits [43]. All patients were given oral hygiene instruction
including tooth brushing and the use of interdental flossing or interdental brushing at each session.
The SDD group was given adjunctive SDD (20 mg per capsule), while the placebo group received
adjunctive placebo capsules (containing inactive filler; i.e., starch) b.i.d for 3 months. Study medication
was advised to be taken once in the morning and once in the evening, 1 h before meals. All patients were
represented with a code and were supplied with 2-week doses of SDD or visually identical placebo
capsules (28 capsules) in coded bottles. Study medications had indistinguishable in appearance.
Obedience was stimulated by giving them in labeled bottles biweekly.
The evaluation stages included; Recall 1, last day of SDD or placebo therapy (3 months); Recall 2,
3 months after the completion of the medication (6 months); Recall 3, 6 months after the completion
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of the medication (9 months); Recall 4, 9 months after the completion of the medication (12 months).
At each recall visit clinical parameters and GCF sampling were repeated. Regular maintenance therapy
was administrated at every visit during the 12-month period and patient was given motivation to
reinforce the oral hygiene. Intra-examiner calibration exercise of the examiner gave 97% reproducibility
(κ = 0.939) within PD and between 2.00 to 10.00 for CAL.
2.3. Gingival Crevicular Fluid (GCF) Sampling
GCF samples were collected from mesiobuccal aspects of a single rooted teeth demonstrating
probing depths of 6–8 mm, distributing in different quadrants in each subject., the supragingival
plaque was removed from the interproximal surfaces with a curette prior to sampling; these surfaces
were dried gently by an air syringe and were isolated by cotton rolls. GCF was collected with filter
paper (ProFlow, Inc., Amityville, NY, USA). Paper strips, carefully inserted into the crevice until mild
resistance was felt, were left there for 30 s [44]. Attention was taken to prevent mechanical injury. Blood
contaminated strips were discarded. The absorbed GCF volume of each strip was determined by an
electronic device (ProFlow, Inc., Amityville, NY, USA). Strips were placed into a sterile polypropylene
tube and kept at −40 ◦C until analysis. The readings from the Periotron 8000 were transformed to an
actual volume (µL) by reference to the standard curve.
2.4. MPO, MMP-9, MMP-13, OPG, and TRAP-5 in GCF by Enzyme-Linked Immunosorbent Assay (ELISA)
and MMP-8 by Immunofluorometric Assay (IFMA) Analysis
GCF MMP-9, MMP-13, myeloperoxidase, OPG, and TRAP-5 were determined by ELISA assays
according to the manufacturer’s instructions (Immunodiagnostic AG, Bensheim, Germany and Human
Biotrac ELISA systems, GE, Healthcare and Amersham, Little Chalfont, UK). GCF samples were
assayed at dilutions of 1:10 for MPO and 1:20 for MMP-13. The MMP-13 ELISA detects native,
complexed, and fragmented MMP-13 species. The MPO detection limit was 1.6 ng/mL and MMP-13
was 0.032 ng/mL. The level of MMP-8 was assayed at a dilution of 1:4 by IFMA. The detection limit
for MMP-8 was 0.08 ng/mL [37].
Total MPO, MMP-8, MMP-9, and OPG data were determined by averaging the sampling sites per
subjects. Results for MPO, MMP-8, MMP-9, and OPG were converted as total MPO, MMP-9, and OPG
(ng/sample) in the GCF sample.
3. Statistical Analysis
Considering a 0.5-mm mean difference between whole mouth PD values of SDD and placebo
groups and assuming the standard deviations to be 0.5 in both groups, sample size calculations were
performed prior to the study. Accepting a power of 85%, a p value of 5%, normal distribution, and equal
variances in the SDD and placebo groups, the minimum required sample size per group was calculated
as 14 subjects. The primary outcome variable was selected as PD. GCF biomarker levels served as
secondary outcome variables. The mean values of the subject whole-mouth clinical parameters and
subject mean values for clinical parameters were averaged. The patient was regarded as the unit of
analysis. Intragroup comparisons of the clinical parameters between baseline and 3, 6, 9, and 12 months
were analyzed by the Friedman test. Bonferroni corrected Wilcoxon signed rank test was used to
analyze the significance of the changes over time. The Mann-Whitney test was used to determine
significant differences between the SDD and placebo groups. Biochemical variables were tested with
the non-parametric model of Brunner-Langer using a web-based software (R software, version 3.3.1,
package: nparLD, R Foundation for Statistical Computing, Vienna, Austria; http://r-project.org).
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4. Results
4.1. Patient Disposition and Demographics
Table 1 presents patient demographics. Gender, ages, and smoking habits of the patients were
similar in both groups (p > 0.05).
Table 1. Demographic characteristics and smoking history of the sub-antimicrobial dose of doxycycline
(SDD) and placebo groups.
SDD Group Placebo Group
Male/Female 11:4 10:5
Mean age, years 48.9 ± 6.6 49.2 ± 7.3
Age range 38–59 40–61
Smokers (n) 7 6
4.2. Clinical Results (Whole Mouth)
The mean values of the subject whole-mouth clinical parameters for the SDD and placebo groups
were given in Table A1. Baseline clinical periodontal parameters were similar between both study
groups (p > 0.05). The periodontal conditions of both SDD and placebo groups markedly enhanced
between baseline and the re-examinations at 3, 6, 9, and 12 months (p < 0.0125). The whole-mouth
mean CAL of the SDD group significantly decreased during the study period (p < 0.0125), while the
whole-mouth CAL scores of the placebo group showed significant improvement at 3 months
(p < 0.0125). There were not any significant changes at other time points (p > 0.0125).
SDD group demonstrated a significantly greater reduction in PD than placebo group at the 6, 9,
and 12 month visits (p = 0.04, p = 0.02, and p = 0.04, respectively), while both showed a similar reduction
in PD at 3 months (p > 0.05). The CAL of the SDD group had greater improvement than the placebo
group which was significant at 6 and 9 months (p = 0.04, p = 0.04, respectively). The whole-mouth
CAL scores were comparable for both study groups for other time points (p > 0.05). GI scores showed
statistically significant improvement in SDD compared to the placebo group at 3, 6, and 9 months
(p = 0.01, p = 0.01, and p = 0.01, respectively). There was a significant reduction in the PI scores of both
groups, but no significant differences detectable between them over the entire study period (p > 0.05).
4.3. Clinical Results (Sampling Sites)
The mean of the clinical parameters and GCF values of the study sites were similar between
both groups at baseline (p > 0.05). Significant improvement was observed at 3 months which was
maintained during the 12-month study period compared to baseline (p < 0.0125). No significant
difference was observed between groups at all time points (p > 0.05). (Table A2).
4.4. GCF MMP-8, MMP-9, MPO, and OPG Levels
GCF TRAP and MMP-13 levels remained below the detection limit in a considerable part of the
study population. MMP-13 could be detected in 15 out of 30 patients and TRAP was detected in 8 of
46 CP patients in the baseline samples.
Figure 1 demonstrates the changes in MMP-8 levels in the GCF samples. SDD and placebo
groups had comparable GCF MMP-8 total amount at baseline (p > 0.05). GCF MMP-8 total amount
significantly decreased in both groups at 12 months compared to baseline (p < 0.05). GCF MMP-8 total
amount in the SDD group tended to show a larger decrease compared to that of the placebo group at
the 6 month mark, but this was not statistically different between groups. GCF MMP-8 total amount
was stabilized for the rest of the study period in both groups.
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decreased in both groups at 12 months compared to baseline (p < 0.05). GCF MMP-9 total amount 
tended to decrease more at the third month in the SDD group compared to placebo group, then a 
similar decrease pattern was observed in both groups. Then, no additional decrease was observed in 
either group, although the levels were still significantly lower than the baseline levels.  
 
Figure 2. GCF MMP-9 total amount (pg/site) in the SDD and placebo groups from baseline to 12 
months. Relative treatment effects as revealed by Brunner-Langer analysis. * Significant difference 
from baseline after SDD therapy or placebo therapy (p < 0.0125).  
Figure 3 outlines the change in MPO levels in the GCF samples. GCF MPO significantly 
decreased in the SDD and placebo groups at all time points compared to baseline (p < 0.05). Similar 
to the GCF MMP-9 pattern, GCF MPO total amount of the SDD group showed more of a decrease at 
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Figure 2 shows the change in MMP-9 levels in the GCF samples. The SDD and placebo groups
had a similar GCF MMP-9 total amount at baseline (p > 0.05). GCF MMP-9 total amount significantly
decreased in both groups at 12 months compared to baseline (p < 0.05). GCF MMP-9 total amount
tended to decrease more at the third month in the SDD group compared to placebo group, then a
similar decrease pattern was observed in both groups. Then, no additional decrease was observed in
either group, although the levels were still significantly lower than the baseline levels.
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Figure 3 outlines the change in MPO levels in the GCF samples. GCF MPO significantly decreased
in the SDD and placebo groups at all time points compared to baseline (p < 0.05). Similar to the GCF
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MMP-9 pattern, GCF MPO total amount of the SDD group showed more of a decrease at the third
month compared to the placebo group, they were similar at the sixth month, and then the placebo
group showed an increased level during the rest of the study. In contrast, GCF MPO levels continued
to decrease over 12 months in the SDD group.
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Figure 4. GCF osteoprotegerin (OPG) total amount (pg/site) in the SDD and placebo groups from 
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Figure 4 demonstrates the change in OPG levels in the GCF samples. The SDD and placebo
groups had a similar GCF OPG total amount at baseline (p > 0.05). GCF OPG total amount significantly
decreased in the SDD and placebo groups at all time points compared to baseline (p < 0.05). The placebo
group showed an increased change from the third month to the twelfth month. In contrast, GCF OPG
levels continued to decrease over 12 months in the SDD group.
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5. Discussion
The efficacy of adjunctive SDD on both clinical parameters and GCF MMP-8, MMP-9, MMP-13,
MPO, TRAP, and OPG levels beyond that obtained by nonsurgical periodontal therapy alone in
chronic periodontitis patients has been investigated in the present double blind, placebo-controlled,
parallel-arm study. Both therapy provided significant improvement in the management of chronic
periodontitis, but adjunctive SDD has more clinical benefit than SRP alone.
Both SDD and placebo groups showed significant improvements in clinical parameters, which was
evident at 3 months and maintained throughout the study period. All patients received adequate
periodontal maintenance therapy at every 3 months after active periodontal therapy [45]. This might
improved oral hygiene conditions throughout the study period in both groups. SRP therapy leads to
the resolution and control of the inflammatory response, facilitates the elimination of a favorable
environment for the colonization of the periodontopathogens, and causes the cessation of the
progression of periodontal disease, thereby resulting in a relative gain of clinical attachment and
reduction of the probing depth [46–48].
In previous studies, SDD was prescribed to chronic periodontitis patients in either combination
with scaling and prophylaxis, or SRP therapy [34–39,49,50]. Our present findings that adjunctive
SDD has more clinical benefit than SRP alone in terms of PD reduction and clinical attachment gain
confirm and further extend the findings previously reported [34–39,49,50]. In our study, SDD was
prescribed for 3 months as an adjunct to SRP. Even though the duration of the drug regimen in our
study was shorter than that of previous studies [38,39,50], clinical improvements observed in deep
and moderate pockets as early as 3 months after commencing drug therapy were similar to those
of previous studies [35,36,38,39,50,51], and importantly, this improvement was maintained until the
end of 12-month study period. This clinical improvement in the SDD group might be attributed to
the effectiveness of nonsurgical periodontal therapy, as well as due to the long-term beneficial-host
modulatory-effect of doxycycline [33,52]. Based on the present data we might suggest that a 3-month
treatment duration may be sufficient for producing prolonged and beneficial effects, which might be
dependent on the substantivity of SDD [33,53].
Due to the complexity of the periodontitis pathogenesis, the balance between pro-inflammatory
and anti-inflammatory mediators is more important than the levels of any single inflammatory
mediator in connective tissue and bone catabolism during the disease progression [2]. The levels and
especially activation of MMP-8, MMP-9, and MMP-13 have been shown to be correlated with active
stages of periodontal disease, and they decrease to levels found in periodontally healthy GCF after
conventional periodontal treatment [5,14,15,33]. MPO, by activating MMPs oxidatively in inflamed
periodontal tissues, could lead to the upregulation of the MMP-dependent proteolytic cascades and
participate in the progression of periodontal disease [10,16,18,23,54–57]. Studies have shown dramatic
elevation of MPO levels in periodontitis, suggesting that MPO could be a useful diagnostic marker for
the activity of the acute inflammation [17,58].
In the present study, the SDD and placebo groups had similar GCF MMP-8, MMP-9, and MPO
levels at baseline. After adjunctive SDD or SRP therapy, GCF MMP-8, MMP-9, and MPO total amount
showed marked reductions throughout the study period. Hence, decreased biomarker levels in both
the SDD and placebo groups’ GCF during active periodontal therapy might suggest the effectiveness
of nonsurgical periodontal therapy (oral hygiene instruction and SRP) in reducing the bacterial load in
the periodontal environment. GCF MMP-8 total amount in the SDD group tended to decrease more
compared to the placebo group at the 6 month mark, although the difference was not statistically
significant. GCF MMP-8 total amount was stabilized for the rest of the study period in both groups.
GCF MMP-9 total amount tended to decrease more at 3 months in the SDD group compared to
the placebo group. Then, no additional decrease was observed in the groups, although the levels
were still significantly lower than the baseline levels. Similar to MMP-9, GCF MPO total amount of
the SDD group showed more of a decrease at 3 months compared to the placebo group, but they
were similar at 6 months. Thereafter, those levels increased for the rest of the study periods in the
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placebo group while the GCF MPO levels continued to decrease over the 12 months in the SDD group.
Based on the present data we might suggest that while mechanical treatment alone led only to a
transient decrease in the levels of these biomarkers, SDD stabilized those enzyme levels for 12 months,
although the results were not statistically significant. In a preliminary study, short term (2 week)
SDD resulted in the reduction of collagenase activity by approximately 60–80%, which indicated
the ability of TCs to decrease the severity of inflammation, thereby blocking the breakdown of the
periodontal tissues [34,52]. Our findings are consistent with others and our previous studies which
demonstrated that adjunctive SDD therapy can reduce the activity or down-regulate the expression of
host collagenases/MMPs by a mechanism unrelated to the antimicrobial efficacy of this drug [37,50–52].
Furthermore, Golub et al. [51] showed that SDD was effective in the suppression of pathologically
excessive collagenases associated with both inflammatory and bone destructive disease and crucial
in the destruction of type I and III collagens found in the periodontal ligament [51]. On the other
hand, fibroblast-type collagenase (MMP-1), which is involved in normal connective tissue remodelling,
has been shown to be relatively resistant to doxycycline inhibition treatment [59]. This selective MMP
inhibition mechanism of doxycycline might provide a safe and effective therapeutic approach for
reducing pathologically excessive collagenases, without interfering with the normal connective tissue
remodelling required to maintain normal tissue integrity. Lee et al. [49] found that 9 months SDD usage
resulted in significantly greater per-patient average in both MMP-8 and MMP-13 activities in the SDD
group compared to placebo group. Several studies confirmed that adjunctive SDD treatment following
SRP suppresses the activity of the tissue destructive enzymes MMP-8 and MMP-13. At present,
quantitative oral fluid chair-side/point-of-care adjunctive diagnostic oral fluid assays are commercially
available for MMP-8 [14,15]. In the present study, MMP-13 could be detected in only about 32% of CP
patient at baseline, therefore, we were unable to evaluate the effect of SDD therapy in CP patients.
MPO can oxidatively promote collagenolytic catabolism, i.e., active periodontal degeneration
with a balance in favor of MMP cascade activation. In the present study, lower GCF MPO levels in the
adjunctive SDD group might suggest that SDD in vivo, and in addition to MMPs, can down-regulate
the levels of MPO, a unique neutrophil-derived oxidative up-regulator of MMPs, at the periodontitis
sites. Our results demonstrate that GCF MMP-8, MMP-9, and MPO levels could be linked to such
reduced oxidative and collagenolytic activities due to their impact on MMP-dependent proteolysis of
the extracellular matrix.
Several placebo-controlled randomized clinical studies have evaluated the adjunctive effect of
SDD therapy on different host response markers in GCF [37,50,60–65]. It has been confirmed that SDD
therapy inhibits the activity or down-regulates the expression of host inflammatory markers other
than MMPs by a mechanism unrelated to the antimicrobial efficacy of this drug [35,37,49]. On the
other hand, treatment of periodontitis with sub-antimicrobial doxycycline failed to reduce the GCF
osteocalcin levels [51].
In the present study, the adjunctive effect of SDD was evaluated for biomarkers of bone turnover,
TRAP and OPG, in GCF for the first time. There are a limited number of studies investigating the
TRAP enzyme, whose biological function is not known in periodontal disease. Shibutani et al. [66]
by staining TRAP and TRAP+ cells observed osteoclastic activity at the alveolar bone surface that
is related to the inflammatory changes in the gingiva in an experimentally induced periodontitis
model in beagle dogs. Crotti et al. [67] and Da Costa et al. [68] observed increased accumulation
of TRAP+ cells in CP patients compared to controls and suggested that the inflammatory response
triggers osteoclastic differentiation in periodontitis lesions. In another experimental periodontitis
study, systemic OPG-Fc sharply decreased serum TRAP-5b levels and stayed low during the study
period [27]. GCF TRAP levels were investigated in CP patients, and TRAP could be detected in about
17% of the samples. OPG is one of the molecules that is a negative regulator of bone resorption and
limits the duration and extent of the immune and inflammatory responses [69]. Localized absence
of OPG in diseased periodontal tissues has been associated with periodontal disease activity and
progression [70,71]. In the present study, the GCF OPG total amount significantly decreased in the SDD
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and placebo groups at all time points compared to baseline. The placebo group showed an increased
level from 3 months to 12 months. In contrast, GCF OPG levels continued to decrease over 12 months
in the SDD group. To the best our knowledge, this is the first study investigating this bone marker in
an SDD group. Previously, Golub et al. [51] observed a significant reduction in pyridoline-containing
collagen breakdown fragments in the GCF of CP patients while osteoclacin levels were unchanged
after the SDD therapy.
In conclusion, SDD medication in combination with SRP therapy improved clinical periodontal
parameters and GCF biomarker levels of chronic periodontitis patients. However, as a limitation of
the present study was that GCF TRAP and MMP-13 levels remained below the detection limit in a
considerable part of the study population. Taken together, these results demonstrate that the long-term
success and efficacy of the SDD treatment is through the MMPs pathway in the periodontal tissues.
The present data might further support the effectiveness of the SDD therapy in adjunct to nonsurgical
periodontal therapy in the management of chronic periodontitis.
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Appendix A
Table A1. The whole mouth (±SD) clinical parameters of SDD and placebo groups.
SDD Group Placebo Group
Baseline 3 months 6 months 9 months 12 months Baseline 3 months 6 months 9 months 12 months
PD (mm) 4.03 ± 0.82 2.65 ± 0.40 * 2.53 ± 0.39 *¶ 2.45 ± 0.52 *¶ 2.42 ± 0.55 *¶ 4.15 ± 0.80 2.86 ± 0.46 * 2.85 ± 0.57 * 2.88 ± 0.61 * 2.89 ± 0.62 *
CAL (mm) 4.71 ± 1.14 4.13 ± 1.03 * 4.16 ± 0.98 *¶ 4.09 ± 1.03 *¶ 4.16 ± 1.00 * 5.19 ± 1.20 4.73 ± 1.01 * 4.86 ± 1.05 4.84 ± 1.06 4.84 ± 1.10
GI 1.82 ± 0.40 0.76 ± 0.33 *¶ 0.83 ± 0.25 *¶ 0.70 ± 0.29 *¶ 0.70 ± 0.35 * 1.89 ± 0.29 1.00 ± 0.30 * 1.02 ± 0.28 * 0.97 ± 0.33 * 0.92 ± 0.33 *
PI 3.84 ± 0.89 1.96 ± 0.74 * 1.97 ± 0.80 * 1.69 ± 0.97 * 1.41 ± 0.73 * 4.18 ± 0.75 2.07 ± 0.72 * 1.95 ± 0.72 * 1.89 ± 0.73 * 1.87 ± 0.70 *
* Significant difference from baseline (p < 0.0125). ¶ Significant difference from placebo group (p < 0.05).
Table A2. Clinical parameters of the study sites of SDD and placebo groups (mean ± SD).
SDD Group Placebo Group
Baseline 3 months 6 months 9 months 12 months Baseline 3 months 6 months 9 months 12 months
PD (mm) 7.05 ± 0.72 3.66 ± 1.00 * 3.16 ± 0.75 * 2.94 ± 1.10 * 2.90 ± 1.04 * 6.68 ± 1.15 3.63 ± 1.37 * 3.58 ± 1.46 * 3.38 ± 1.37 * 3.55 ± 1.40 *
CAL (mm) 7.58 ± 1.49 5.53 ± 2.31 * 5.26 ± 1.81 * 5.21 ± 1.84 * 4.90 ± 2.16 * 7.90 ± 1.69 6.35 ± 1.93 * 6.53 ± 1.98 * 6.13 ± 2.09 * 6.35 ± 2.09 *
GI 2.11 ± 0.49 0.50 ± 0.62 * 0.61 ± 0.52 * 0.32 ± 0.45 * 0.26 ± 0.39 * 1.78 ± 0.59 0.68 ± 0.49 * 0.65 ± 0.67 * 0.58 ± 0.65 * 0.43 ± 0.61 *
PI 3.68 ± 0.87 1.92 ± 0.92 * 1.82 ± 1.26 * 1.82 ± 1.38 * 1.32 ± 0.84 * 4.05 ± 1.18 1.85 ± 1.01 * 1.78 ± 0.94 * 2.00 ± 1.15 * 2.18 ± 1.31 *
GCF (µl) 1.12 ± 0.35 0.54 ± 0.22 * 0.38 ± 0.16 * 0.55 ± 0.26 * 0.50 ± 0.24 * 0.98 ± 0.40 0.42 ± 0.23 * 0.48 ± 0.31 * 0.49 ± 0.26 * 0.53 ± 0.28 *
* Significant difference from baseline (p < 0.0125).
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